Key facts
- Cartography Biosciences’s last known valuation is $135.3M (May 2025).
- It has raised $143.0M; the latest was Later Stage VC ($80.0M) in May 2025.
- Notable investors include Andreessen Horowitz, Gaingels, 8VC, Calm Ventures, Alexandria Venture Investments — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Cartography Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Cartography Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cartography Biosciences
Operator of a biotechnology company intended to develop cancer therapies via precision medicine. The company offers a platform-based cell therapy that utilizes single-cell analysis to identify novel Chimeric Antigen Receptor T-cell (CAR-T) targets, enabling pharmaceutical researchers and oncology developers to develop molecular biology and computational methods for the advancement of cancer immunotherapies.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2020
- Employees
- 48
- Website
- cartography.bio/
- Ownership
- Privately Held (backing)
Cartography Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cartography Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cartography Biosciences in its N-PORT filings yet. We sweep new filings monthly.